Abstract: Systemic sclerosis (SSc) is a connective disease characterized by features of autoimmunity, vasculopathy, infl ammation, and fi brosis. The disease typically starts with Raynaud's phenomenon, followed by skin thickening in the extremities due to infl ammation and fi brosis. Fibrosis results from excessive collagen production by fi broblasts, which constitutes the fi nal common pathway of complex cellular interactions including B cells. Several studies have indicated that B cells may play a role in SSc. Lesional skin infi ltrates from SSc patients consist of a variety of cells, including eosinophils, neutrophils, lymphocytes, plasma cells, and macrophages. Autoantibodies of several specifi cities are present in the serum of SSc patients of which antitopoisomerase 1 is the most common, and evidence has been gathered for a potential pathogenic role of some autoantibodies, eg, anti-PDGF antibodies. The blood of SSc patients contains an increased proportion of naïve B cells but a decreased proportion of memory B cells. Furthermore, serum levels of interleukin-6, an important pro-infl ammatory cytokine, have been shown to correlate with skin fi brosis. Animal models of SSc have provided more in-depth information on the role of B lymphocytes, eg, through disruption of B cell function. In this review we will discuss the evidence that B cells are involved in the pathogenesis of SSc.
Introduction
Systemic sclerosis (SSc) is a systemic autoimmune, connective tissue disease characterized by infl ammation, vascular endothelial dysfunction, specifi c immunologic abnormalities, and tissue fi brosis due to an imbalance between collagen production and degradation. Although its phenotypic characteristics are heterogeneous and disease course variable, two different clinical subtypes can be identifi ed, the limited cutaneous form (lSSc) and the diffuse cutaneous form of SSc (dSSc). The lSSc subset is characterized by skin thickening of the face, neck, and distal aspects of the limbs, by ischemic digital loss, and an increased prevalence of isolated pulmonary hypertension. The dSSc subset involves skin of the proximal limbs as well and affects visceral organs, including the lung, heart, gastrointestinal tract, and kidneys, especially at late stages. The prevalence of SSc in females is higher than in males and in blacks than in whites (Mayes et al 2003) . The average age at diagnosis is lower for blacks than for whites, and blacks have about a twice higher chance to develop dSSc. A positive family history is the strongest risk factor for SSc, although the absolute risk for each family member remains low (Arnett et al 2001) .
SSc is believed to be caused by the interaction of genetic and environmental factors (Jimenez and Derk 2004; Abraham and Varga 2005; Denton and Black 2005) , leading to a loss of immune tolerance. T and B lymphocytes are responsible for the establishment and maintenance of tolerance as illustrated by the observation that alterations in B cell signaling result in autoimmunity. B cell signaling is modulated by response regulators, such as CD19 (Goodnow 1996; Conrad et al 2007) . For example, combined binding of CD19 with the antigen-receptor of B lymphocytes decreases the antigen receptor-stimulation threshold a 100-fold (Carter and Fearon 1992) . CD19 can also form a complex with CD21, the receptor for fragments of the third complement component (C3), which amplifi es the BCR-signal. This binding of C3 to the CD19-CD21 complex links innate with humoral immunity (Tedder et al 1997) . CD22 is a negative regulator of the BCR complex, terminating signal transduction (Asano et al 2004) . Both CD19 and CD22 have their own regulatory network for the BCR complex; CD19 expression causes CD22 phosphorylation, while CD22 expression is responsible for the inhibition of CD19 (Fujimoto et al 1999; Fujimoto and Sato 2007) . This CD19/CD22 loop suggests a regulation-balance of autoimmunity in B cells. In keeping with this, transgenic mice overexpressing CD19 showed increased serum levels of autoantibodies, indicating that CD19 overexpression disrupts tolerance in B cells . Interestingly, CD22 defi cient mice also had increased levels of autoantibodies indicating that CD22 defi ciency alone is suffi cient to induce autoimmunity (O'Keefe et al 1999) .
Whatever the precise abnormal immunological mechanism underlying SSc, the aforementioned studies do illustrate how subtle B cell abnormalities lead to survival and activation of self-reactive B cells, production of autoantibodies and autoimmune disease (Lipsky 2001; Youinou 2007) .
Pathological features of SSc
Dermal fi brosis typically starts in the extremities with an infl ammatory phase characterized by mononuclear infi ltration (Fleischmajer et al 1983) , which will then progress to fi brosis. Although the exact process is not known, it is suggested that as infl ammation subsides, fi brosis increases (Sakkas 2005) . In the skin, thickening of the dermis is found showing accumulation of dense collagen, whereas in the lower dermis small vessels showed fi brous thickening (Fleischmajer et al 1977; Jiminez and Derk 2004 ). An early study on skin biopsies, using hematoxylin and eosin (H&E) stainings, showed cellular infi ltrates consisting of lymphocytes, plasma cells, and macrophages in 49% of 65 SSc patients (Fleischmajer et al 1977) . Hussein and colleagues (2005) 
Autoantibodies in SSc
Autoantibodies are present in 95% of SSc patients, and are either specifi c for SSc or have overlap with other connective diseases (Meyer 2006) . The autoantibodies antitopoisomerase 1 (anti-Topo 1, Scl-70), anti-RNA polymerase III, and anti-U3 RNP are associated with dSSc, whereas others, like anticentromere, anti-U1 RNP, anti-PmScl, and anti-Th/To are associated with lSSc. The incidence rates of these autoantibodies vary among different ethnic groups (Kuwana et al 1999; Reveille et al 2001) . In a study of 1,432 cases from the Pittsburgh Scleroderma Databank, 10-year survival was linked to autoantibody status. In patients with lSSC the 10-year survival was 75% in patients positive for anticentromere antibody, 88% for those with anti-U1 RNP, 72% in those with anti-PmScl, and 65% in patients with anti-Th/To autoantibodies. For dSSC patients the 10-year survival was 64% for patients with anti-Topo 1, 75% for patients with anti-RNA polymerase III, and 61% in those with anti-U3 RNP autoantibodies (Steen 2005) . Different autoantibodies are associated with different clinical manifestations. ILD is associated with anti-Topo 1, pulmonary hypertension with anticentromere antibodies, anti-3U RNP, and antiTh/To, whereas renal hypertension is associated with RNA polymerase III antibodies (Meyer 2006) . Anti-Topo1 is the most common autoantibody (10%-30%) in dSSc (Tan et al 1988; Kuwana et al 1994) . Its serum levels correlate positively with disease activity and disease severity in SSc (Hu 2003) . Moreover, loss of anti-Topo 1 has been associated with clinical improvement (Kuwana et al 2000) .
More recently, other autoantibodies have been detected in the sera of SSc patients (Arnett 2006) . These include antiendothelial cell antibodies (AECAs), antifi brillin-1 (anti-FBN1) antibodies, antibodies against matrix metalloproteinases (MMP), and antiplatelet-derived growth factor receptor (PDGFR) antibodies. Some of the AECAs have been shown to bind to the human cytomegalovirus late protein UL94, and induce endothelial cell apoptosis via the interaction with the cell surface integrin-NAG-2 protein complex (Lunardi et al 2000) . Anti-FBN1 antibodies activate normal fi broblasts resulting in the increased production of ECM components (Zhou et al 2005) . Anti-PDGFR autoantibodies induce collagen 1 production by reactive oxygen species cascades, and convert resting fi broblasts into myofi broblasts (Baroni et al 2006) . Further autoantibodies found in SSc patients include antifi broblast antibodies (AFA), which are capable of binding to the surface of fi broblasts (Chizzolini et al 2002) , and autoantibodies against the molecular chaperone heat-shock protein 47 (HSP47) . The presence of circulating, potentially functional, autoantibodies argues in favor of a pathogenic role of B cells in SSc.
Other immunological abnormalities in SSc
B cells, among other cells, secrete interleukin-6 (IL-6), which stimulates fi broblasts to produce collagen. In a mouse scleroderma model, B cell depletion using an anti-mouse CD20 monoclonal antibody led to a decrease in IL-6 mRNA levels and a reduction of fi brosis . IL-6 serum levels and spontaneous IL-6 production by peripheral blood mononuclear cells (PBMCs) are higher in SSc patients compared with normal controls. In addition, it was shown that IL-6 serum levels correlate with skin fi brosis (Sato et al 2001) . Thus, IL-6 may be an important target for the treatment of SSc in humans. Other cytokines may also be involved. In SSc patients elevated levels of IL-4, IL-8, IL-10, IL-12, IL-13, and IL-17 were found, suggesting that both B and T cells are involved in the pathogenesis of SSc ( IL-4, IL-6, and IL-13 stimulate the synthesis of collagen by fi broblasts, leading to excessive scar formation and fi brosis (Duncan and Berman 1991; Wynn 2004) . One of the key cytokines involved in tissue fi brosis is transforming growth factor-β (TGF-β) (Varga and Abraham 2007) . Human B lymphocytes, amongst other cells, can be a source of TGF-β and express receptors for TGF-β (Kerhl et al 1986) . TGF-β promotes collagen deposition and inhibits collagen degradation by decreasing MMPs and increasing the tissue inhibitors of metalloproteinases (TIMP) expression (Verrecchia et al 2007) . Serum TIMP-1, but not MMP-1 levels, are elevated in SSc patients compared with normal controls, indicating that collagen accumulation results from inhibition rather than a decrease in MMPs (Young-Min et al 2001) . Flowcytometric analysis of peripheral blood mononuclear cells from SSc patients showed an increased number of naïve B cells, but a decreased number of memory B cells and plasmablasts (Sato et al 2004) . CD19 expression was increased in both naïve and memory B cells, but only memory B cells had an activated phenotype with increased expression of CD80, CD86, and CD95 suggesting chronic activation. Another study showed a 20% higher CD19 and CD21 cell surface density in blood samples from SSc patients compared with normal controls, but similar expression levels of CD20, CD22, and CD40 (Sato et al 2000b) . SSc patients have elevated levels of B lymphocyte stimulator (BAFF) (Matsushita et al 2006) . SSc B cells showed increased levels of BAFF receptor (BAFFR) as well, indicating a pathogenic role of B cells caused by BAFF. BAFF combined with BCR ligation stimulates B cell activity, and was shown to rescue some self-reactive B cells from death (Schneider et al 1999; Thien et al 2004) . Another role of BAFFR is the upregulation of Bcl-2 expression as well as nuclear factor kappa-B (NF-κB) activation, favoring B cell survival (Do et al 2000) . These studies indicate that BAFF might promote the survival of B cells, thereby contributing to autoimmunity in SSc.
Animal models of SSc
There are several mouse models with features of SSc (summarized in Table 1 ). The University of California, Davis (UCD) line 200 chickens have numerous immunopathologic and serologic features in common with human scleroderma (Gershwin et al 1981) . As early as 7 days, lymphocytic infi ltration with T and B cells, followed by fi brosis and B cells in systemic sclerosis vascular occlusion of the skin, feet, and comb can be observed (Van de Water et al 1989; Gruschwitz et al 1991) Infi ltration of CD4 + cells precedes that of CD8 + and B cells, but during maturation of the skin lesion B cell clusters increase in size, and in mature lesions distinct B and T cell areas are recognized. Also antinuclear antibodies, antibodies to collagen and rheumatoid factor can be detected in this model, as well as antiendothelial cell antibodies (Sgonc et al 1996) . In another model, the injection of bleomycin into the skin of mice results in histological dermal changes with thickened and homogenous collagen bundles and cellular infi ltrates consisting mainly of CD4 + lymphocytes, mast cells and macrophages similar to human scleroderma skin. Bleomycin treatment also leads to the production of serum autoantibodies (Yamamoto et al 1999; Yamamoto 2006) . In MRL/lpr mice defi cient for interferon-gamma (IFN-γ) (MRL/lprγR-/-) histological changes are described resembling human scleroderma, such as accumulation of collagen and mononuclear cell infi ltration with T and B cells, and macrophages in connective tissue of several organs as well as intima thickening (Le Hir et al 1999) .
The tight-skin (TSK) mouse is a third model of SSc, and although it does not share all its phenotypic characteristics, autoantibodies are found against SSc-specifi c target autoantigens including Topo I, fi brillin 1 (Fbn-1), RNA polymerase I, collagen type I, and Fcγ receptors (Bona and Rothfi eld 1994) . It is believed that the TSK phenotype is caused by an internal duplication within the fi brillin 1 gene, resulting in a 3 kb larger transcript compared with the wildtype transcript (Siracusa et al 1996) . Mice homozygous for this mutation die in utero, while heterozygous (TSK/+) mice survive and develop cutaneous fi brosis, pulmonary emphysema, and cardiac hypertrophy (Saito et al 2000; Fujimoto and Sato 2007) . The immunological abnormalities are not well understood, however. The infusion of bone marrow cells of TSK/pa mice into pa/pa littermates resulted in sclerodermalike skin changes with thickening of the deep dermis and a diffuse, interstitial mononuclear infi ltrate, consisting of activated lymphocytes, plasma cells and activated macrophages three months later, preceded by a rise in anti-RNA polymerase 1 and Topo 1 autoantibodies (Phelps et al 1993) . In another study in the TSK/+ mouse model it was shown that CD19 defi ciency resulted in reduction of skin thickness in these mice (Saito et al 2002) . Due to this defi ciency, IL-6 production by TSK/+ B cells as well as autoantibody production in TSK/+ mice was decreased, showing that there is a CD19 dependent signalling pathway in B cells contributing to systemic autoimmunity and skin sclerosis in TSK/+ mice.
A more recent mouse model has been a modifi ed model of graft-versus-host (GVH)-induced SSc. The injection of spleen cells from B10.D2 mice into BALB/c mice defi cient in mature T and B cells induces a disease resembling SSc with dermal thickening, progressive fi brosis in internal organs, vasculopathy, and presence of autoantibodies (Ruzek et al 2004) .
Summary
The fi ndings from a number of (pre)clinical studies point to a potential role for B lymphocytes in the pathogenesis of systemic sclerosis. These include abnormal B cell signalling in TSK/+ mice, the presence of B cells and expressed B cell genes in skin biopsies from SSc patients, abnormalities in numbers and activation status of B cells in peripheral blood, the presence of serum autoantibodies and elevated serum levels of cytokines such as IL-6 which correlate with skin fi brosis. B cells could contribute to fi brosis through several mechanisms, depicted in Figure 2 . The stage is set for clinical trials to investigate whether B cell depletion in SSc is effective as in other autoimmune diseases (Looney 2002; Browning 2006; Blank and Shoenfeld 2007) . Preliminary results from a pilot study in SSc patients with rituximab, a chimeric anti-CD20 monoclonal antibody are encouraging (Bosello et al 2007) .
Nevertheless, our understanding of the precise contribution of B lymphocytes in the early stages in the pathogenesis of systemic sclerosis is limited, and some of the evidence circumstantial. Further studies are therefore needed to dissect the specifi c contribution of B lymphocytes in the pathogenesis of systemic sclerosis.
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